Caraco Pharmaceutical Laboratories Ltd has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market tizanidine hydrochloride, a generic form of Elan Pharmaceutical's Zanaflex, Narendra N. Borkar, Chief Executive Officer, announced.
Tizanidine is a short-acting muscle relaxant prescribed for the management of spasticity and has a U.S. market of approximately $240 million.
He noted that the Company has two additional drugs pending FDA approval.
Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures and distributes generic and private-label prescription drugs to some of the nation's largest wholesalers, distributors, drugstore chains, healthcare systems and state and federal agencies.